Enanta Pharmaceuticals (ENTA) Accumulated Expenses (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Accumulated Expenses of $6.9 million for Q1 2026, down 77.64% year-on-year from $30.7 million in Q1 2025, and up 185.67% on a QoQ basis from $2.4 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Accumulated Expenses data on file, last reported at $6.9 million in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses fell 77.64% year-over-year to $6.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (down 77.64% YoY), and the FY2025 full-year result was $12.8 million, down 5.88% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $6.9 million, up from $2.4 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $36.7 million in Q2 2023 and bottomed at $2.4 million in Q4 2025.
- The 5-year median for Accumulated Expenses is $6.9 million (2026), against an average of $13.7 million.
- Peak annual rise in Accumulated Expenses reached 934.07% in 2025, while the deepest fall reached 85.22% in 2025.
- A 5-year view of Accumulated Expenses shows it stood at $15.2 million in 2022, then plunged by 71.58% to $4.3 million in 2023, then retreated by 5.03% to $4.1 million in 2024, then sank by 41.34% to $2.4 million in 2025, then soared by 185.67% to $6.9 million in 2026.
- The last three Accumulated Expenses figures came in at $6.9 million (Q1 2026), $2.4 million (Q4 2025), and $12.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.86 Mn |
| Dec 31, 2025 | 2.40 Mn |
| Sep 30, 2025 | 12.75 Mn |
| Jun 30, 2025 | 4.77 Mn |
| Mar 31, 2025 | 30.68 Mn |
| Dec 31, 2024 | 4.09 Mn |
| Sep 30, 2024 | 13.55 Mn |
| Jun 30, 2024 | 32.30 Mn |
| Mar 31, 2024 | 2.97 Mn |
| Dec 31, 2023 | 4.31 Mn |
| Sep 30, 2023 | 35.08 Mn |
| Jun 30, 2023 | 36.69 Mn |
| Mar 31, 2023 | 3.08 Mn |
| Dec 31, 2022 | 15.16 Mn |
| Sep 30, 2022 | 6.44 Mn |
| Jun 30, 2022 | 19.19 Mn |
| Mar 31, 2022 | 2.96 Mn |
| Dec 31, 2021 | 26.58 Mn |
| Sep 30, 2021 | 6.09 Mn |
| Jun 30, 2021 | 17.70 Mn |
| Mar 31, 2021 | 2.59 Mn |
| Dec 31, 2020 | 11.54 Mn |
| Sep 30, 2020 | 4.78 Mn |
| Jun 30, 2020 | 3.48 Mn |
| Mar 31, 2020 | 1.97 Mn |
| Dec 31, 2019 | 9.41 Mn |
| Sep 30, 2019 | 3.89 Mn |
| Jun 30, 2019 | 14.00 Mn |
| Mar 31, 2019 | 11.61 Mn |
| Dec 31, 2018 | 1.45 Mn |
| Sep 30, 2018 | 9.89 Mn |
| Jun 30, 2018 | 9.13 Mn |
| Mar 31, 2018 | 1.43 Mn |
| Dec 31, 2017 | 5.70 Mn |
| Sep 30, 2017 | 2.83 Mn |
| Jun 30, 2017 | 5.63 Mn |
| Mar 31, 2017 | 5.10 Mn |
| Dec 31, 2016 | 960,000.00 |
| Sep 30, 2016 | 2.38 Mn |
| Jun 30, 2016 | 4.58 Mn |
| Mar 31, 2016 | 2.63 Mn |
| Dec 31, 2015 | 3.17 Mn |
| Sep 30, 2015 | 3.96 Mn |
| Jun 30, 2015 | 3.47 Mn |
| Mar 31, 2015 | 2.91 Mn |
| Dec 31, 2014 | 584,000.00 |
| Sep 30, 2014 | 2.87 Mn |
| Jun 30, 2014 | 2.98 Mn |
| Mar 31, 2014 | 562,000.00 |
| Dec 31, 2013 | 1.72 Mn |
| Sep 30, 2013 | 1.04 Mn |
| Jun 30, 2013 | 2.02 Mn |
| Mar 31, 2013 | 493,000.00 |
| Sep 30, 2012 | 1.31 Mn |